Bruker • Microbiology & Infection Diagnostics’ Post

You can only say YES to a MALDI Biotyper®. Here's why: Accelerate your microbial identification with MBT Compass HT IVD software, designed to maximize the power of your MALDI Biotyper® IVD System. With a faster analysis speed of up to 600 samples/hour and the ability to prioritize urgent samples, this software can significantly improve your lab's efficiency. The zero-button IDealTune™ feature ensures optimal performance without extra cost or effort. Plus, the new IVD solution for the identification of filamentous fungi expands your system's capabilities. Move to MBT Compass HT IVD and take your clinical microbiology to the next level! #BrukerMID #microbiology #diagnostics #MALDIBiotyper #clinicalmicrobiology #fungi #GOTsirius

Building confidence in IVD Controls for POCT - Our swab format controls are developed to mimic samples throughout the full process of the test procedure. Manufacturing third-party IVD controls is complex but we want to assure newcomers to our controls that they are as easy-to-use as the tests themselves. Enjoy the cartoon The full Microbiologics video 'How to use inactivated Helix Elite™ swabs' can be watched on https://bit.ly/3wc8IV8 Contact BioConnections at https://bit.ly/3RoAELx #IPC #POCT #BedsideTest #IVDR #QualityControl #Microbiology #healthcareinfectionsociety

𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗼𝗶𝘀𝗲𝗱 𝘁𝗼 𝗚𝗿𝗼𝘄 𝗮𝘁 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 6.9% 🔰 Request Free Sample Report-https://lnkd.in/d-jiPiyw The global in vitro diagnostics market in terms of revenue was estimated to be worth $85.2 billion in 2024 and is poised to reach $119.4 billion by 2029, growing at a CAGR of 6.9% from 2024 to 2029 🔰 Key Recent Product Launches - ELITechGroup launched the CE-IVDR certified gastrointestinal (GI) bacterial PLUS ELITe MGB kit in January 2024. This kit is designed to detect bacterial pathogens associated with gastrointestinal infections, expanding their product portfolio in the IVD sector. - HORIBA Medical FRANCE (HORIBA ABX SAS) introduced a high-throughput automated hematology platform in January 2024, also certified under CE-IVDR. This platform is aimed at improving analytical performance in laboratories, catering to the increasing need for efficient hematology testing. The major players in this market are Roche, Abbott, Danaher Corporation, Siemens Healthineers, and Thermo Fisher Scientific #IVDmarket #diagnosticsindustry #medicaltechnology #healthcareinnovation #precisionmedicine #clinicaldiagnostics #biomarkers #pointofcaretesting #molecularbiology #lifesciences

Elevate your C. difficile testing protocols with our comprehensive solutions. From highly sensitive GDH EIA to cutting-edge molecular tests for antigens and toxins, we offer a complete suite of tools to enhance your patient management system. Our ready-to-use quality control biomaterials also ensure accuracy and reliability in both antigen and molecular testing. The Clostridium K-Set (1520) is a highly sensitive rapid in vitro test for detecting c.diff antigens in stool specimens within 15 minutes. The C. difficile positive control (P-1020) is made from GDH extracted from C. difficile in a lyophilised format. Ideal for use with the Clostridium K-Set and other C. difficile enzyme immunoassays, it ensures precision in your diagnostic endeavours. Explore our extensive range of molecular biomaterials, setting the standard for excellence in external IVD controls. Our C. difficile molecular panels, available in sets of 2 or 6, offer cost-effective and reliable solutions for validating your assays across multiple platforms. Simplify your testing workflow with the eazyplex® C. difficile panel, which enables swift detection of C. diff in a single step or provides confirmatory tests for toxin presence. Three distinct panels catering to varied diagnostic needs deliver results directly from stool samples in just 25 minutes! Ready to optimise efficiency in your laboratory's C. difficile testing? Contact us for more information on how our solutions can streamline your processes and elevate diagnostic accuracy: https://bit.ly/4b8M6o0. #CdiffTesting #Microbiology #QualityControl #MolecularBiomaterials #RapidDiagnostics 

Hemophilia is a blood disease where clotting doesn’t function well, causing excessive bleeding that can be disabling or life-threatening. It’s caused by deficiencies in clotting factors: factor VIII for hemophilia A and factor IX for hemophilia B (B is the rarer form). Hemophilia is treated by infusing the missing clotting factors 1 or more times per week. However, about 1/3 of patients develop neutralizing antibodies called inhibitors that stop the medicine from working. Instead of replacing clotting factors to restore clotting, marstacimab blocks a natural anticoagulant to "rebalance" the equilibrium between coagulation and anticoagulation. As a result, this medicine could be useful in people with hemophilia A or B and with inhibitors. These sorts of innovations are why I love signaling cascades, especially when we see in practice how we can target different parts to bypass the pathobiological basis for a genetic or acquired disease. #medicine #hemophilia #coagulation #biologics #clotting

Aldosterone (ALD) is a key steroid hormone produced by the adrenal gland and commonly tested for primary aldosteonism diagnosis. Snibe is dedicated in developing chemiluminescence immunoassay (CLIA) and has launched new genaration aldosterone assay based on novel small molecule sandwich method for aldosterone detection. Snibe has also successfully established a candidate reference method for the determination of serum/plasma aldosterone using isotope dilution UHPLC-MS/MS, for those laboratories where there is no reference measurements. This method showcases excellent accuracy and precision, offering significant traceability for IVD manufacturers. Discover how we get results in a quick 7 minutes and linearity with a correlation coefficient of 0.9997. #ClinicalChemistry #MassSpectrometry #Aldosterone #BiomedicalResearch #SnibeDiagnostic #Snibe

🔬 Dive Into #AntibodyDrugConjugate #Pharmacokinetics With Our Advanced Immunoassay (#ELISA) And Mass Spectrometry (#LCMS) Capabilities 🔍 ⚖️ Achieve Efficacy & Safety: Balance The Scales With Comprehensive #PK Analysis And #DrugDrugInteraction Profiling, Securing Your Transition From Research To #ClinicalTrials  📊 Review #Biodistribution & Catabolism: Direct The Progression From #InVitro #Potency Assays To #InVivo Tissue Distribution, Shaping Therapeutic Strategies For Superior Patient Outcomes  🛠️ Assess Linker Stability & Deconjugation: Reveal The Resilience Of ADC #Linkers Across Varied #Biological Systems, Customizing Precise Human PK Dosing Regimens 💡Partner With NorthEast Biolab For One-Stop #Bioanalytical Expertise In ADC PK And Beyond. Let’s Embark On Your #DrugDevelopment Voyage As We Unravel The Complexities Of ADCs To Forge Pathbreaking Treatments! https://lnkd.in/dw2ra3KM

The HCPprofiler Standard Qualification Report validates HCPprofiler kit for precise identification and quantification of Host Cell Proteins (HCPs) using LC-MS/MS. The report confirms: Scope: The HCPprofiler combines a peptide-coated bead standard and proprietary software to generate calibration curves for HCP quantification. Validation: The method demonstrates strong specificity, accuracy, precision, and robustness, adhering to ICH Q2(R2) guidelines. Validation covers a broad working range (1-500 fmol), with high linearity (R² ≥ 0.90), accuracy (82%-119%), and repeatability (CVs ≤ 15%). Reproducibility: Tested across batches, instruments, and labs, showing CVs ≤ 21%. Application: Successfully quantifies HCPs in therapeutic peptide drug substances with high repeatability. The report concludes that the HCPprofiler kit is a reliable and robust tool for accurate HCP quantification in various matrices. https://lnkd.in/gFqZcNsy

Regulatory Compliant Tissue Microarrays These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Each TMA features multiple normal tissue types from 3 different donor samples on a single slide to enable simultaneous analysis and facilitate the identification of potential cross-reactive and off-target epitopes that have not been previously observed. Gaining this insight early in the discovery process can help prevent costly mistakes that lead to inaccurate diagnostic test results or unwanted side effects from a therapeutic agent. #news #magazine #update #engineering AMSBIO https://lnkd.in/eKzYJTH4

Discover how optimizing phasing in genotyping can improve PGx workflows. Our latest article reveals how accurate haplotype determination with advanced tools like Intelliseq Polygenic boosts precision in drug response predictions, ensuring optimal treatment plans🌟 🔗 Read the full article: https://lnkd.in/eM6cth34 #Pharmacogenomics #PersonalizedMedicine #Genotyping #Phasing